An interventional study of Acute phase proteins in Immune Thrombocytopenia, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 1 Year to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.
Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Sohag University.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is the only one that started in 2024, is one of 5 with no phase, and was the 6th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →6 of the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Sohag University · Sites in Egypt
Healthy volunteers
Sohag University
Ages 18–60
Sohag University
Ages 1–18 · Healthy volunteers
Sohag University
Ages 16+ · Healthy volunteers
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 100 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 100 across the 5 interventional studies, 45 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07046013Sohag UniversityLevel of Serum Lactate Dehydrogenase in Immune Thrombocytopenia | 2027-06 |
| NCT07014904Sohag University"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children" | 2027-06-04 |
| NCT07900334Sohag UniversityStudy of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients | 2027-09-25 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in thrombocytopenia Acute phase proteins (APP) are inflammation markers that exhibit significant changes in serum concentration during inflammation. These are also important mediators produced in the liver during acute and chronic inflammatory states. Acute phase reactants can be classified as positive or negative, depending on their serum concentrations during inflammation. Positive acute phase reactants are upregulated, and their concentrations increase during inflammation. Negative acute phase reactants are downregulated, and their concentrations decrease during inflammation. Positive acute phase proteins include procalcitonin, C-reactive protein, ferritin, fibrinogen, hepcidin, and serum amyloid A. Negative acute phase reactants include albumin, prealbumin, transferrin, retinol-binding protein, and antithrombin CRP is now well established as a major acute phase protein and is used in daily clinical practice as a sensitive biomarker for infection and inflammation, with its level increasing from \<0.05 to >500 mg/L after acute infections. CRP is produced by hepatocytes, in response to inflammatory cytokines such as interleukin (IL)-6 and IL-1, with serum concentrations rising to >5 mg/L after 6 hours and peaking after ∼48 hours. In healthy young adult volunteer blood donors, the median concentration of CRP was found to be ∼0.8 mg/L CRP levels are useful as a clinical diagnostic tool for infection, and it is a common knowledge that ITP is triggered by viral infection that precedes the clinical picture of ITP by a few days to a few weeks Procalcitonin (PCT) is used as a reliable inflammatory biomarker with high sensitivity and specificity ferritin was confirmed as an inflammation and infection biomarker in the diagnosis of viral and bacterial infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age of patients : from 1 year to 50 years.
Exclusion Criteria:
Other causes of thrombocytopenia as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Causes of decreased platelets count other than immune thrombocytopenia
Diagnostic Test: Acute phase proteins
Patients diagnosed as acute thrombocytopenia
Diagnostic Test: Acute phase proteins
Patients diagnosed as chronic thrombocytopenia
Diagnostic Test: Acute phase proteins
Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
Acute phase proteins
By taking serum samples from pateints and measure acute phase proteins levels
Time frame: 2 years
Plan to share: Undecided
Started Nov 2024 (actual). Primary completion is estimated for Dec 2025, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →